DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for breast adenocarcinoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBreast adenocarcinoma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for breast adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Breast adenocarcinoma remains the most frequent cancer in women and accounts for almost 20% of all cancer deaths, yet the abstracts supplied contain no clinical trial data, no survival statistics from interventional studies, and no quantitative response rates for any specific drug. The 2012 and 2020 reviews describe genetic aberrations and molecular subtypes as poorly understood drivers of initiation and progression, and they attribute past treatment failure to a lack of specific etiology and molecular mechanisms. The 2022 and 2024 overviews list surgery, chemotherapy, hormonal therapy, gene therapy, immunotherapy, and radiation as standard or emerging options, but they explicitly state that breast cancer is a complex disease ranging in severity and pathology, making a universal treatment elusive and requiring combined therapies. A 2011 text on standard limited-stage care mentions lumpectomy, axillary node dissection, regional radiation, and chemotherapy or hormone therapy for unfavourable prognostic factors, supported by American and European randomised trials, but gives no numerical outcomes. A 2008 review claims novel biotherapies are well tolerated and show encouraging responses, while a 2017 review repeats that treatment relies primarily on surgery, radiotherapy, and systemic therapy, with molecular targets still under investigation.
The only quantitative finding in the set comes from a 2021 bioinformatics study of miR-133a-1 in SKBR3 breast cancer cells. Patients with high miR-133a-1 expression showed longer overall survival than those with low expression, but no hazard ratio, confidence interval, or median survival time is reported. Overexpression of miR-133a-1 for 48 hours produced 1,216 differentially expressed genes (653 upregulated, 563 downregulated), with MOCS3 most upregulated and KRT14 most downregulated; SOX9 and CD44 were hub nodes in the protein-protein interaction network, and SOX9 was proposed as a possible target. This is cell-line and computational work only, not a therapeutic intervention, and no drug is named or tested in any abstract.
There is no evidence here that any drug repurposing candidate has been evaluated in patients with breast adenocarcinoma. The abstracts are reviews, a legal text on phantom risks in bakery shops, and one preclinical miRNA study. No abstract reports tumour shrinkage, progression-free survival, overall survival benefit, or toxicity data from a treatment arm. The claims of "encouraging responses" in 2008 and "upward trajectory towards finding a cure" in 2022 are unsupported by any numbers in the supplied material.
What is missing is decisive: randomised controlled trial data with patient-level outcomes, reproducible biomarker stratification (for example, by miR-133a-1 or SOX9 status), and funding for prospective validation of any molecular target. Without those, the reviews and bioinformatic predictions cannot be translated into a clinical recommendation, and the heterogeneity of the disease means no single agent is likely to work across all subtypes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Carcinogenesis & Mutagenesis · 2012 · 8 citations · open access
Epidemiology of Genetic Alterations in Progression of Breast Cancer
AbstractBreast cancer is the most frequent cancer in women responsible for almost 20% of all cancer deaths. Certain aberrations in the genes results higher risk in the development of breast cancer. The present review aims to consolidate a comprehensive role of different genes involved in the development of breast cancer. This helps to know the intracellular molecular changes in tumorigenic pathways within the mammary gland.
Journal of Student Research · 2022 · 2 citations · open access
Recent Advances In Breast Cancer Treatments
AbstractBreast cancer is one of the most deadly cancers. Some of the therapies that target breast cancer include surgery, chemotherapy, hormonal therapy, gene therapy, immunotherapy, and radiation. Newer treatment types introduce new ideas and technologies that are fostering new breast cancer treatments. However, breast cancer is a complex disease that ranges in severity and pathology, thereby making a universal treatment elusive. Current strategies to treat breast cancer involve combining multiple therapies. In this review article, I will describe the evolution of breast cancer treatments and its upward trajectory towards finding a cure.
Translational Cancer Research · 2021 · 2 citations · open access
An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer
AbstractBackground: The microRNA (miRNA) miR-133a-1 has been identified as a tumor suppressor in breast cancer. However, the underlying mechanisms of miR-133a-1 in breast cancer have not been fully elucidated. This study aimed to explore the targets of miR-133a-1 in breast cancer using an integrated bioinformatics approach. Methods: Human SKBR3 breast cancer cells were transfected with miR-133a-1 or a miRNA negative control (miRNA-NC) for 48 hours. The RNA-seq sequencing technique was performed to identify the differential expression of genes induced by miR-133a-1 overexpression. Functional enrichment analysis was conducted to determine the target genes and pathways involved in breast cancer. Results: Breast cancer patients with high levels of miR-133a-1 expression commonly showed longer overall survival compared to patients with a low level of miR-133a-1 expression. Using Cuffdiff, we identified 1,216 differentially expressed genes induced by miR-133a-1 overexpression, including 653 upregulated and 563 downregulated genes. MOCS3 was the most upregulated gene and KRT14 was the most downregulated gene. The top 10 pathways related to the differentially expressed genes were identified through Gene Ontology (GO) enrichment analysis. Sex-determining region Y-box 9 (SOX9) demonstrated the highest semantic similarities among the differentially expressed genes. Since SOX9 and CD44 were hub nodes in the protein-protein interaction network, the SOX9 gene may be a target of miR-133a-1 in breast cancer. Conclusions: This report provides useful insights for understanding the underlying mechanisms in the pathogenesis of breast cancer.
Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer
AbstractBreast cancer is the most common and highly heterogeneous neoplastic disease comprised of several subtypes with distinct molecular etiology and clinical behaviours. The mortality observed over the past few decades and the failure in eradicating the disease is due to the lack of specific etiology, molecular mechanisms involved in the initiation and progression of breast cancer. Understanding of the molecular classes of breast cancer may also lead to new biological insights and eventually to better therapies. The promising therapeutic targets and novel anti-cancer approaches emerging from these molecular targets that could be applied clinically in the near future are being highlighted. In addition, this review discusses some of the details of current molecular classification and available chemotherapeutics.
AbstractBreast cancer is one of the most common cancers worldwide, affecting millions of individuals annually. Advances in medical research have brought about a variety of treatment options tailored to different types and stages of the disease. This article provides a comprehensive overview of breast cancer treatment methods, including surgical procedures, chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation therapy, and supportive care like palliative treatments. Each treatment approach is discussed in detail, emphasizing its purpose, effectiveness, and role in managing breast cancer. Designed for patients, caregivers, and the general public, this guide aims to demystify breast cancer treatment and provide a foundational understanding of the available options.
Europaisches wirtschafts und steuerrecht · 2011 · 0 citations
Über Phantomrisiken und hygienerechtliche Anforderungen an SB-Backshops: Reflexionen zur Vorlagefrage des UVS Wien in der Rechtssache C-382/10
AbstractStandard treatment for limited stage adenocarcinoma of the breast includes lumpectomy (or a quadrantectomy), axillary node dissection, regional radiation therapy and, if the prognostic factors are unfavourable, chemotherapy and/or hormone therapy. This is supported by the results of American and European randomised trials. There have been many attempts at improving the modalities of conservative surgery and postoperative radiation therapy in order to maximize local control and minimize late sequellae. It is also likely that induction chemotherapy and external beam radiotherapy applied in selected cases increase the proportion of patients who can be offered conservative surgery.
AbstractSurgical resection, adjuvant chemotherapy and radiotherapy have been widely accepted to be the major therapy for breast cancer nowadays. With the rapid development of biotechniques, some novel therapies including molecular target therapy, gene therapy and immunotherapy are now under clinical investiga-tion. They are proved to be well tolerated and show encouraging responses in patients with breast cancer.
Key words:
Breast neoplasms; Gene therapy; Immunotherapy; Targeted therapy
Biosciences Biotechnology Research Asia · 2017 · 0 citations · open access
Molecular Targeted Therapy for Breast Cancer: A New Frontiers
AbstractABSTRACT: Cancer has become a major public health problem worldwide. Researches focus on the new approaches for cancer treatments that involve the specific targets of the cancer disease. Breast cancer is the most frequent type of cancer among women, and it causes approximately 25% of the deaths in women below the age of 35. Multiple environmental and hereditary factors are responsible for breast cancer such as age, family history, postmenopausal obesity, early menarche, late menopause, alcohol consumption, pregnancy and the use of exogenous hormones. Treatment of breast cancer patients relies primarily on surgery followed by radiotherapy and systemic therapy. Several molecules expressed and secreted by breast cancer cells have been identified by their interactions, invasion and metastasis. These molecular interactions appear to maintain the cancer cells’ survival and growth. The improvement in understanding of the molecular basis of breast cancer will provide possible targets for novel therapies. Therefor, this review focuses on the molecular and cellular basis of the breast cancer treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
